Fortuno,

Nice find. Yes, they should be looking our way for many reasons that have been previously discussed here. CYDY fits GILD's hand like a glove, both in HIV and Oncology !!! Highlights of O'Day comments at the STAT Summit (bold highlights and color are mine) below:

Quote:

---

Gilead, which had about $25 billion in cash at the end of the last quarter, is “in an acquisitive mode,” he said

---

Quote:

---

In the meantime, Gilead is still piecing together its third act. The company made its name in virology, with blockbuster medicines for HIV and hepatitis C, but its forays into cancer medicine have led to mixed results. Gilead’s $12 billion acquisition of Kite Pharma, maker of CAR-T immunotherapies, has yet to prove itself as a wise investment.

---

Quote:

---

The path forward, O’Day said, is finding avenues in oncology where Gilead can stand out from its competition, rather than investing in me-too ideas that would fight for diminishing returns. That means picking battles.

---

Quote:

---

“I honestly believe that the elimination of HIV is within our grasp in the U.S.,” O’Day said. “We’re firmly focused on that."

---